PDEXHealthcare · Medical Instruments & SuppliesThe 1 Wall Street analysts covering Pro-Dex, Inc. hold a median 12-month price target of $74 — +2.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Pro-Dex, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PDEX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Sept 2026 | Ascendiant Capital | Maintains | Buy | $70 → $74 |
| 12 May 2026 | Ascendiant Capital | Maintains | Buy | — |
| 12 May 2026 | Ascendiant Capital | Maintains | Buy | $56 → $70 |
| 27 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Feb 2025 | Ascendiant Capital | Maintains | Buy | — |
| 11 Nov 2024 | Ascendiant Capital | Maintains | Buy | — |
| 9 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 4 Jan 2017 | Ascendiant Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PDEX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Pro-Dex, Inc. returned +108.7% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 41% of US stocks
Cheaper than 41% of US stocks
Cheaper than 21% of US stocks
Cheaper than 19% of US stocks
Higher than 65% of US stocks
Higher than 87% of US stocks
Higher than 41% of US stocks
Higher than 75% of US stocks
Higher than 80% of US stocks
Higher than 89% of US stocks
Higher than 95% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pro-Dex, Inc. has a market value of $232.4M and an enterprise value of $242.0M.
Revenue in the twelve months to 30 June 2026: $77.5M. The latest quarter grew 16.6% year on year.
Net income over the same four quarters: $13.7M, a 17.6% net margin.
Free cash flow in the twelve months to 30 June 2026: $6.8M.
Pro-Dex, Inc. spent $3.4M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 17.6×; forward P/E: 21.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Pro-Dex, Inc. employs 201 people — $386K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pro-Dex, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reported that Pro-Dex, Inc. (PDEX), along with APH and RELY, was added to its Zacks Rank #1 (Strong Buy) momentum stocks list on September 18th, 2026.
Why it matters — A PDEX watcher would care because inclusion on Zacks' Strong Buy momentum list signals a positive research rating for the stock at that time.
On September 18th, 2026, Pro-Dex, Inc. (PDEX) was added to the Zacks Rank #1 (Strong Buy) List, along with PGY, OPHC, TRV, and HMN, as reported by Zacks Investment Research.
Why it matters — Being added to the Zacks Rank #1 (Strong Buy) List marks a notable recognition of PDEX by the research firm, which PDEX watchers would monitor.
Pro-Dex, Inc. announced its financial results for the fiscal 2026 fourth quarter and full year ended June 30, 2026. The announcement was made on September 3, 2026, from the company's Irvine, CA headquarters.
Why it matters — A PDEX watcher would care because the results provide an official update on the company's fourth-quarter and full-year financial performance.
The 1 Wall Street analysts covering Pro-Dex, Inc. have a median 12-month price target of $74, with estimates ranging from $74 to $74. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Pro-Dex, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pro-Dex, Inc. 94 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Pro-Dex, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +2.0% from the last close, and Ticker Nerd's factor model ranks Pro-Dex, Inc. 94 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pro-Dex, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PDEX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $74 over the next 12 months.
Pro-Dex, Inc. returned +108.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Pro-Dex Inc. is a medical equipment and contract manufacturing company that designs, develops, and manufactures powered surgical instruments for healthcare original equipment manufacturers.
The most recent item we track (Zacks Investment Research, 18 Sept 2026): "Best Momentum Stocks to Buy for September 18th". Zacks Investment Research reported that Pro-Dex, Inc. (PDEX), along with APH and RELY, was added to its Zacks Rank #1 (Strong Buy) momentum stocks list on September 18th, 2026.
Pro-Dex Inc. is a medical equipment and contract manufacturing company that designs, develops, and manufactures powered surgical instruments for healthcare original equipment manufacturers. Pro-Dex Inc. focuses on autoclavable, battery-powered, and electric surgical drivers and shavers used in orthopedic, thoracic, and craniomaxillofacial procedures. The company also provides engineering, quality, and regulatory consulting services, supporting customers from product design through production. In addition, it produces rotary air motors and related precision components for a range of industrial applications. Pro-Dex Inc. serves medical device distributors, OEMs, and other industrial customers, making it an important supplier in specialized precision manufacturing and surgical technology markets. Headquartered in Irvine, California, Pro-Dex Inc. combines contract manufacturing capabilities with in-house design expertise to deliver customized medical and industrial solutions.
CEO Mr. Richard Lee Van Kirk Jr. · 201 employees · United States · https://www.pro-dex.com
